Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4.17 USD
Change Today 0.00 / 0.00%
Volume 0.0
MNKD On Other Exchanges
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

mannkind corp (MNKD) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/30/14 - $11.48
52 Week Low
05/1/15 - $4.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MANNKIND CORP (MNKD)

mannkind corp (MNKD) Details

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

287 Employees
Last Reported Date: 03/2/15
Founded in 1991

mannkind corp (MNKD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $748.8K
Founder and Executive Chairman
Total Annual Compensation: $858.6K
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $466.0K
Chief Operating Officer and Corporate Vice Pr...
Total Annual Compensation: $479.2K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $409.2K
Compensation as of Fiscal Year 2014.

mannkind corp (MNKD) Key Developments

Mannkind Corporation to Manufacture 12 Unit Cartridge Strength of AFREZZA (R) Following FDA Approval

MannKind Corporation announced that it will begin to manufacture a 12 unit cartridge strength of AFREZZA (insulin human) Inhalation Powder to improve glycemic control in adult patients with diabetes. The 12 unit cartridge was approved by the U.S. Food and Drug Administration on April 17, 2015 and is expected to be launched by Sanofi in the second half of 2015. The new dosage strength complements the existing 4 unit and 8 unit cartridges and will provide patients with another option to receive their prescribed dose.

MannKind Corp. Auditor Raises 'Going Concern' Doubt

MannKind Corp. filed its 10-K on Mar 02, 2015 for the period ending Dec 31, 2014. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

MannKind Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

MannKind Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s net loss applicable to common stockholders was $36.44 million or $0.09 per basic and diluted share compared to net loss to common shareholders of $53.58 million, or $0.16 per basic and diluted share in 2013. Loss from operations was $30,103,000 compared to $46,617,000 a year ago. The net loss applicable to common stockholders for 2014 was $198.4 million or $0.51 per basic and diluted share, slightly higher than the net loss to common shareholders of $191.5 million, or $0.64 per basic and diluted share in 2013. Loss from operations was $179,627,000 compared to $169,401,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNKD:US $4.17 USD 0.00

MNKD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MNKD.
View Industry Companies

Industry Analysis


Industry Average

Valuation MNKD Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MANNKIND CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at